Gilead Sciences, Inc.

Gilead Connecticut, Inc.

Genentech, Inc.

Kronos Bio, Inc.

Cgi Pharmaceuticals, Inc.

Genetech, Inc.

Zhongdong Zhao

Kevin S Currie

Peter A Blomgren

Jeffrey E Kropf

Scott A Mitchell

Jianjun Xu

Seung H Lee

Aaron C Schmitt

Jennifer R Lo

Jin-Ming Xiong

Sundaramoorthi Swaminathan

Kirk L Stevens

Jayaraman Chandrasekhar

Pavel E Zhichkin

Leena Patel

Christopher T Clark

Yasamin Moazami

Jason K Perry

Nicole Nava

Natalie Seeger

Taryn Campbell

Jennifer Anne Treiberg

Xiaojing Wang

Daniel Fred Ortwine

Wendy B Young

Suet Chung Yeung

Julian Andrew Codelli

Stephane Perreault

Douglas Gregory Stafford

Kassandra F Sedillo

Antonio J M Barbosa

William John Watkins

Chandrasekar Venkataramani

Juan A Guerrero

Zhimin Du

Honglu Zhang

Ravi Krishnamoorthy

David M Armistead

Antonio J M Barbosa, Jr

Soumya Mitra

James P Harding

Jeff A Zablocki

John O Link

Hyung-Jung Pyun

Scott E Lazerwith

Zheng-Yu Yang

Peiyuan Wang

Darryl Kato

Barton W Phillips

Sheila M Zipfel

Gregory Notte

Devan Naduthambi

Jiayao Li

Joshua A Kaplan

Adam James Schrier

Michael Sangi

Ashley Anne Katana

Julie Farand

Julie A Di Paolo

Astrid Clarke

David R Brittelli

John Edward Knox, Jr

Antonio J Barbosa

John E Knox, Jr

Nicholas Mai

William Martin Rennells

JinMing Xiong

Peter Blomgren

Douglas G Stafford

William M Rennells

Jinming Xiong

Jr Antonio J Barbosa

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Quinoline derivatives

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

Compounds for inhibition of &#x3b1;4 &#x3b2;7 integrin

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2: 

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Compounds for inhibition of alpha 4 beta 7 integrin

Compounds for inhibition of &#x3b1;4&#x3b2;7 integrin

Imidazopyridine derivatives

Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Imidazopyridines Syk inhibitors

Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyridone and aza-pyridone compounds and methods of use

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R, R, R, and Rare as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

Compounds having the following formula (I) and methods of their use and preparation are disclosed: 

Tank-binding kinase inhibitor compounds

Growing community of inventors

Guilford, CT, United States of America

Zhongdong Zhao